Lexaria notes FDA approval of Eli Lilly's oral weight-loss drug Foundayo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 7, 2026 9:10 AM EDTThe number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects
KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq: LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration ("FDA") has approved Eli Lilly and Company's® Foundayo glucagon-like peptide-1 ("GLP-1") agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical... More
